Guangzhou Aobo Pharmaceutical Technology

Guangzhou Aobo Pharmaceutical Technology is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of innovative ophthalmic therapeutics. The company's lead program is a novel formulation of loxoprofen sodium, a non-steroidal anti-inflammatory drug (NSAID) that acts as a cyclooxygenase (COX) inhibitor, currently in Phase 3 clinical trials for the treatment of postoperative pain and inflammation. In collaboration with the Guangdong Lewwin Pharmaceutical Research Institute, Aobo is also exploring the use of loxoprofen sodium for other ocular conditions such as dry eye syndrome. The company's pipeline includes various ophthalmic delivery formats, including eye drops, gels, and ointments, aimed at improving patient outcomes in eye care through enhanced drug delivery and efficacy.